Study findings suggest serum phosphate is a negative modulator of calcium receptor activation.
Patiromer may be another therapeutic option for patients with both hyperkalemia and hyperphosphatemia.
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
In a small Canadian study, investigators found that patients switched from conventional to in-center nocturnal hemodialysis experience improvements in various measures of health-related quality of life, especially mental health.
Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.